Table 1

Prediction of repeat biopsy results by PSAD and PSAV

Cancer
(n = 23)
 Non-Cancer
(n = 104)
 P
 sensitivity
 specificity
 PPV
 NPV
PSAV (ng/ml year)

0.0004
 78%
 63%
 32%
 93%
     ≥ 0.80
 18 (78%)
 39
(37%)




     <0.80
 5 (22%)
 65
(63%)




PSAD (ng/mL2)

0.12
 61%
 67%
 29%
 89%
     ≥ 0.30
 14 (61%)
 34
(33%)




     <0.30
 9 (39%)
 70
(67%)




PSAV ≥ 0.80 and PSAD ≥ 0.30
 12 (52%)
 15
(14%)
 6.2 × 10-5
 52%
 86%
 44%
 89%
PSAV ≥ 0.80 and PSAD < 0.30
 6 (26%)
 24
(23%)




PSAV < 0.80 and PSAD ≥ 0.30
 2 (9%)
 19
(18%)




PSAV < 0.80 and PSAD < 0.30
 3 (13%)
 46
(44%)
 0.0054
 87%
 44%
 26%
 94%

Abbreviations: PSA, prostate specific antigen; PSAD, PSA density; PSAV, PSA velocity; PPV, positive predictive value; NPV, negative predictive value.

Yuasa et al. BMC Urology 2008 8:14   doi:10.1186/1471-2490-8-14